Shots: Innovent to receive $200M up front, $825M as development and commercial milestones along with royalties on net sales of the therapy. Both the companies will retain the right to study Tyvyt in combination with other therapies as part of their own clinical programs Lilly will get an exclusive license for the therapy for geographies […]Read More
Shots: The NMPA has accepted the sNDA for Tyvyt (sintilimab) in combination with Gemzar (gemcitabine) and platinum as 1L therapy in sq. NSCLC The sNDA is based on P-III ORIENT-12 study assessing sintilimab (200mg) vs PBO in combination with Gemzar and Pt (q3w for up to 4 or 6 cycles), followed by either sintilimab or […]Read More
Shots: The collaboration allows MD Anderson to conduct multiple clinical studies for multiple rare cancer indications. MD Anderson plans to develop an approach, upon commercialization in rare diseases and will receive royalties on sales of the product in the US, used it to fund for uninsured patients The focus of the collaboration is to advance […]Read More
Shots:sstosohShots: The P-II ORIENT-2 study involves assessing TYVYT as monothx. vs paclitaxel/ rinotecan in 190 patients in a ratio (1:1) with advanced or metastatic ESCC who failed 1L treatment The P-II ORIENT-2 resulted in meeting its 1EPs of OS with no news safety signals. The detailed results will be presented at ASCO 2020. The two […]Read More
Shots: The companies collaborated to jointly assess safety and efficacy of Chipscreen’s Chidamide in combination with Innovent’s Sintilimab + IBI305 in patients with advanced colorectal carcinoma (ACC) The focus of the agreement is to explore the combination in clinical applications of immune check-point inhibitor, angiogenesis inhibitor and epigenetic modulator in ACC Chidamide is a HDAC […]Read More
Copyright ©2020 PharmaShots | Powered by Octavus Consulting
